Pericarditis in malignancy approach to treatment: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Pericarditis in malignancy}} | {{Pericarditis in malignancy}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. | {{CMG}}; '''Associate Editor-In-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. | ||
==Treatment== | ==Approach to Treatment== | ||
It is important to assess the life expectancy of the patients before proceeding with the treatment. Patients with advanced malignancy should be treated palliatively with [[pericardiocentesis]] to improve their symptoms. While those with better prognosis should be treated more aggressively. | It is important to assess the life expectancy of the patients before proceeding with the treatment. Patients with advanced malignancy should be treated palliatively with [[pericardiocentesis]] to improve their symptoms. While those with better prognosis should be treated more aggressively. | ||
Asymptomatic or minimally symptomatic patients should be treated conservatively with avoidance of volume depletion, antineoplastic therapy and regular followup. | Asymptomatic or minimally symptomatic patients should be treated conservatively with avoidance of volume depletion, antineoplastic therapy and regular followup. | ||
Symptomatic patients should undergo prompt drainage of effusion which could be done either by [[pericardiocentesis]] or surgical creation of [[pericardial window]]. | Symptomatic patients should undergo prompt drainage of effusion which could be done either by [[pericardiocentesis]] or the surgical creation of a [[pericardial window]]. | ||
Recurrence of pericardial effusion is frequently observed following simple pericardiocentesis<ref name="pmid10725950">{{cite journal| author=Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH et al.| title=Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. | journal=Mayo Clin Proc | year= 2000 | volume= 75 | issue= 3 | pages= 248-53 | pmid=10725950 | doi= | pmc= | url= }} </ref><ref name="pmid8624876">{{cite journal| author=Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Lorell BH, Simons M| title=Pericardial effusion in patients with cancer: outcome with contemporary management strategies. | journal=Heart | year= 1996 | volume= 75 | issue= 1 | pages= 67-71 | pmid=8624876 | doi= | pmc=PMC484225 | url= }} </ref> | Recurrence of pericardial effusion is frequently observed following simple pericardiocentesis.<ref name="pmid10725950">{{cite journal| author=Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH et al.| title=Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. | journal=Mayo Clin Proc | year= 2000 | volume= 75 | issue= 3 | pages= 248-53 | pmid=10725950 | doi= | pmc= | url= }} </ref><ref name="pmid8624876">{{cite journal| author=Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Lorell BH, Simons M| title=Pericardial effusion in patients with cancer: outcome with contemporary management strategies. | journal=Heart | year= 1996 | volume= 75 | issue= 1 | pages= 67-71 | pmid=8624876 | doi= | pmc=PMC484225 | url= }} </ref> The following techniques are adapted in order to prevent fluid from re-accumulating: | ||
#'''Prolonged pericardiocentesis:'''<ref name="pmid10725950">{{cite journal| author=Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH et al.| title=Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. | journal=Mayo Clin Proc | year= 2000 | volume= 75 | issue= 3 | pages= 248-53 | pmid=10725950 | doi= | pmc= | url= }} </ref><ref name="pmid10197666">{{cite journal| author=Allen KB, Faber LP, Warren WH, Shaar CJ| title=Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. | journal=Ann Thorac Surg | year= 1999 | volume= 67 | issue= 2 | pages= 437-40 | pmid=10197666 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10197666 }} </ref> | #'''Prolonged pericardiocentesis:'''<ref name="pmid10725950">{{cite journal| author=Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH et al.| title=Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. | journal=Mayo Clin Proc | year= 2000 | volume= 75 | issue= 3 | pages= 248-53 | pmid=10725950 | doi= | pmc= | url= }} </ref><ref name="pmid10197666">{{cite journal| author=Allen KB, Faber LP, Warren WH, Shaar CJ| title=Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. | journal=Ann Thorac Surg | year= 1999 | volume= 67 | issue= 2 | pages= 437-40 | pmid=10197666 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10197666 }} </ref> A catheter should not be removed until the drainage is < 20-30 ml/24 hours. Intermittent catheterization is recommended to maintain catheter patency. | ||
#'''Pericardial sclerosis:''' Obliteration of pericardial cavity using [[tetracycline]], [[doxycycline]]<ref name="pmid8955660">{{cite journal| author=Liu G, Crump M, Goss PE, Dancey J, Shepherd FA| title=Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. | journal=J Clin Oncol | year= 1996 | volume= 14 | issue= 12 | pages= 3141-7 | pmid=8955660 | doi= | pmc= | url= }} </ref> | #'''Pericardial sclerosis:''' Obliteration of a pericardial cavity using [[tetracycline]], [[doxycycline]],<ref name="pmid8955660">{{cite journal| author=Liu G, Crump M, Goss PE, Dancey J, Shepherd FA| title=Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. | journal=J Clin Oncol | year= 1996 | volume= 14 | issue= 12 | pages= 3141-7 | pmid=8955660 | doi= | pmc= | url= }} </ref> [[minocycline]],<ref name="pmid6726303">{{cite journal| author=Davis S, Rambotti P, Grignani F| title=Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases. | journal=J Clin Oncol | year= 1984 | volume= 2 | issue= 6 | pages= 631-6 | pmid=6726303 | doi= | pmc= | url= }} </ref> [[bleomycin]],<ref name="pmid19156149">{{cite journal| author=Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M et al.| title=A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). | journal=Br J Cancer | year= 2009 | volume= 100 | issue= 3 | pages= 464-9 | pmid=19156149 | doi=10.1038/sj.bjc.6604866 | pmc=PMC2658533 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19156149 }} </ref> or talc. | ||
#'''[[Pericardiotomy]]:''' | #'''[[Pericardiotomy]]:''' Pericardiotomy describes the surgical creation of a pericardial window that drains fluid into the [[pleural cavity|pleural]] or [[peritoneal cavity]] as fluid accumulates in the pericardial sac. In the presence of hemodynamic instability, pericardial fluid must be removed first by pericardiocentesis, and then it is ok to proceed with surgery. To a large extent, this avoids further instability or cardiovascular collapse during induction of general anesthesia.<ref name="pmid9337306">{{cite journal| author=DeCamp MM, Mentzer SJ, Swanson SJ, Sugarbaker DJ| title=Malignant effusive disease of the pleura and pericardium. | journal=Chest | year= 1997 | volume= 112 | issue= 4 Suppl | pages= 291S-295S | pmid=9337306 | doi= | pmc= | url= }} </ref> | ||
Patients with [[constrictive pericarditis]] should be treated with pericardial stripping also known as [[pericardiectomy]] provided that the prognosis from the malignancy justifies surgery. It is not recommended in patients with mild constriction and in advanced stages of malignancy due to operative risk of 6-12%<ref name="pmid10500037">{{cite journal| author=Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB et al.| title=Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. | journal=Circulation | year= 1999 | volume= 100 | issue= 13 | pages= 1380-6 | pmid=10500037 | doi= | pmc= | url= }} </ref><ref name="pmid1863142">{{cite journal| author=DeValeria PA, Baumgartner WA, Casale AS, Greene PS, Cameron DE, Gardner TJ et al.| title=Current indications, risks, and outcome after pericardiectomy. | journal=Ann Thorac Surg | year= 1991 | volume= 52 | issue= 2 | pages= 219-24 | pmid=1863142 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1863142 }} </ref> | Patients with [[constrictive pericarditis]] should be treated with pericardial stripping also known as [[pericardiectomy]] provided that the prognosis from the malignancy justifies surgery. It is not recommended in patients with mild constriction and in advanced stages of malignancy due to an operative risk of 6-12%.<ref name="pmid10500037">{{cite journal| author=Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB et al.| title=Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. | journal=Circulation | year= 1999 | volume= 100 | issue= 13 | pages= 1380-6 | pmid=10500037 | doi= | pmc= | url= }} </ref><ref name="pmid1863142">{{cite journal| author=DeValeria PA, Baumgartner WA, Casale AS, Greene PS, Cameron DE, Gardner TJ et al.| title=Current indications, risks, and outcome after pericardiectomy. | journal=Ann Thorac Surg | year= 1991 | volume= 52 | issue= 2 | pages= 219-24 | pmid=1863142 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1863142 }} </ref> | ||
'''Intrapericardial chemotherapy''' is another approach in treatment of recurrent effusion. [[Cisplatin]] has shown to reduce the incidence of recurrence by up to 93% at | '''Intrapericardial chemotherapy''' is another approach in treatment of recurrent effusion. [[Cisplatin]] has shown to reduce the incidence of recurrence by up to 93% at 3 months and 83% at 6 months followup.<ref name="pmid20728703">{{cite journal| author=Maisch B, Ristic A, Pankuweit S| title=Evaluation and management of pericardial effusion in patients with neoplastic disease. | journal=Prog Cardiovasc Dis | year= 2010 | volume= 53 | issue= 2 | pages= 157-63 | pmid=20728703 | doi=10.1016/j.pcad.2010.06.003 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20728703 }} </ref><ref name="pmid12323163">{{cite journal| author=Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R| title=Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. | journal=Eur Heart J | year= 2002 | volume= 23 | issue= 20 | pages= 1625-31 | pmid=12323163 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12323163 }} </ref> | ||
==References== | ==References== | ||
| Line 26: | Line 26: | ||
[[Category:Inflammations]] | [[Category:Inflammations]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Cardiology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 15:05, 27 November 2017
|
Pericarditis in malignancy Microchapters |
|
Differentiating Pericarditis in malignancy from other Diseases |
|---|
|
Diagnosis |
|
Case Studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Approach to Treatment
It is important to assess the life expectancy of the patients before proceeding with the treatment. Patients with advanced malignancy should be treated palliatively with pericardiocentesis to improve their symptoms. While those with better prognosis should be treated more aggressively.
Asymptomatic or minimally symptomatic patients should be treated conservatively with avoidance of volume depletion, antineoplastic therapy and regular followup.
Symptomatic patients should undergo prompt drainage of effusion which could be done either by pericardiocentesis or the surgical creation of a pericardial window.
Recurrence of pericardial effusion is frequently observed following simple pericardiocentesis.[1][2] The following techniques are adapted in order to prevent fluid from re-accumulating:
- Prolonged pericardiocentesis:[1][3] A catheter should not be removed until the drainage is < 20-30 ml/24 hours. Intermittent catheterization is recommended to maintain catheter patency.
- Pericardial sclerosis: Obliteration of a pericardial cavity using tetracycline, doxycycline,[4] minocycline,[5] bleomycin,[6] or talc.
- Pericardiotomy: Pericardiotomy describes the surgical creation of a pericardial window that drains fluid into the pleural or peritoneal cavity as fluid accumulates in the pericardial sac. In the presence of hemodynamic instability, pericardial fluid must be removed first by pericardiocentesis, and then it is ok to proceed with surgery. To a large extent, this avoids further instability or cardiovascular collapse during induction of general anesthesia.[7]
Patients with constrictive pericarditis should be treated with pericardial stripping also known as pericardiectomy provided that the prognosis from the malignancy justifies surgery. It is not recommended in patients with mild constriction and in advanced stages of malignancy due to an operative risk of 6-12%.[8][9]
Intrapericardial chemotherapy is another approach in treatment of recurrent effusion. Cisplatin has shown to reduce the incidence of recurrence by up to 93% at 3 months and 83% at 6 months followup.[10][11]
References
- ↑ 1.0 1.1 Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH; et al. (2000). "Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy". Mayo Clin Proc. 75 (3): 248–53. PMID 10725950.
- ↑ Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Lorell BH, Simons M (1996). "Pericardial effusion in patients with cancer: outcome with contemporary management strategies". Heart. 75 (1): 67–71. PMC 484225. PMID 8624876.
- ↑ Allen KB, Faber LP, Warren WH, Shaar CJ (1999). "Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage". Ann Thorac Surg. 67 (2): 437–40. PMID 10197666.
- ↑ Liu G, Crump M, Goss PE, Dancey J, Shepherd FA (1996). "Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade". J Clin Oncol. 14 (12): 3141–7. PMID 8955660.
- ↑ Davis S, Rambotti P, Grignani F (1984). "Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases". J Clin Oncol. 2 (6): 631–6. PMID 6726303.
- ↑ Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M; et al. (2009). "A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)". Br J Cancer. 100 (3): 464–9. doi:10.1038/sj.bjc.6604866. PMC 2658533. PMID 19156149.
- ↑ DeCamp MM, Mentzer SJ, Swanson SJ, Sugarbaker DJ (1997). "Malignant effusive disease of the pleura and pericardium". Chest. 112 (4 Suppl): 291S–295S. PMID 9337306.
- ↑ Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB; et al. (1999). "Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy". Circulation. 100 (13): 1380–6. PMID 10500037.
- ↑ DeValeria PA, Baumgartner WA, Casale AS, Greene PS, Cameron DE, Gardner TJ; et al. (1991). "Current indications, risks, and outcome after pericardiectomy". Ann Thorac Surg. 52 (2): 219–24. PMID 1863142.
- ↑ Maisch B, Ristic A, Pankuweit S (2010). "Evaluation and management of pericardial effusion in patients with neoplastic disease". Prog Cardiovasc Dis. 53 (2): 157–63. doi:10.1016/j.pcad.2010.06.003. PMID 20728703.
- ↑ Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R (2002). "Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin". Eur Heart J. 23 (20): 1625–31. PMID 12323163.